Casdin Capital

Founded 2012
Founders Eli Casdin

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 134
Average round size
info
The average size of a deal this fund participated in
$88M
Portfolio companies 91
Rounds per year 10.11
Lead investments 12
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 35
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Genetics
  • Health Care
  • Medical
  • Therapeutics
Summary

Casdin Capital appeared to be the VC, which was created in 2011. The leading representative office of defined VC is situated in the New York. The company was established in North America in United States.

The fund is constantly included in 2-6 investment rounds annually. This Casdin Capital works on 13 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. Considering the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top amount of exits for fund were in 2018. The typical startup value when the investment from Casdin Capital is more than 1 billion dollars.

The usual cause for the fund is to invest in rounds with 7-8 partakers. Despite the Casdin Capital, startups are often financed by The Column Group, ARCH Venture Partners, Topspin Partners. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Redmile Group, Wellington Management. In the next rounds fund is usually obtained by Redmile Group, Perceptive Advisors, GV.

We also calculated 2 valuable employees in our database.

The fund has no exact preference in some founders of portfolio startups. When startup sums 1 of the founder, the probability for it to get the investment is little. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Flatiron Health, 23andMe. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

LetsGetChecked

Health Care
Health Diagnostics
Medical
Late Stage Venture
150M08 Jun 2021 United States, New York

NiKang Therapeutics

Biotechnology
Health Care
Medical
Late Stage Venture
200M26 May 2021
United States, Wilmington

Vedere Bio

Biotechnology
Health Care
Therapeutics
Early Stage Venture
77M18 May 2021 United States, Cambridge

Dyno Therapeutics

Artificial Intelligence
Biotechnology
Health Care
Early Stage Venture
100M06 May 2021 United States, Cambridge

NeoGenomics

Biotechnology
Genetics
Health Care
Health Diagnostics
Medical
Pharmaceutical
200M05 May 2021 United States, Fort Myers

Affinia Therapeutics

Biotechnology
Health Care
Life Science
Therapeutics
Early Stage Venture
110M03 May 2021 United States, " United States"}

Exscientia

Artificial Intelligence
Biotechnology
Pharmaceutical
Late Stage Venture
225M27 Apr 2021 United Kingdom, Oxford

C2i Genomics

Genetics
Health Care
Health Diagnostics
Therapeutics
Wellness
Early Stage Venture
100M15 Apr 2021 United States, New York

Early Stage Venture
20M14 Apr 2021
News
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes
– Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, announced that it has raised $61 million to fuel the continued development of its platform to design and develop new therapeutics mined from microbial genomes. – Nextech Invest led the financing, with participation from new investors SoftBank Vision Fund 2* and Casdin Capital, as well as existing investors The Column Group, 8VC, and Two Sigma Ventures. – Hexagon’s interdisciplinary platform combines... Read more
ROME Therapeutics Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform
– ROME Therapeutics announced the completion of a $77m Series B financing round. – The round was led by new investor Section 32 and included participation from Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments. – ROME’s mission is to harness the power of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats – to discover powerful new classes of medicines for cancer and autoimmune diseases. – ROME... Read more

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Casdin Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: